SYROS PHARMACEUTICALS

Syros Pharmaceuticals is a biopharmaceutical company. The company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The company's key product candidates are: SY-1425, a selective retinoic acid receptor alpha, agonist that is being evaluated in combination with azacitidine, a hypomethylating agent used to treat acute myeloid leukemia and myelodysplastic syndrome patients, and with daratumumab, an anti-CD38 therapeutic antibody approved to treat multiple myeloma; and SY-1365, a selective inhibitor of cyclin-dependent kinase 7, in a Phase 1 clinical trial in patients with advanced solid tumors.
  • TickerSYRS
  • ISINUS87184Q1076
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

A director bought 209,424 shares at 9.550USD and

A director at Syros Pharmaceuticals Inc bought 209,424 shares at 9.550USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The n...

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

ValuEngine Rating and Forecast Report for SYRS

GlobalData Department

Syros Pharmaceuticals Inc (SYRS) - Medical Equipment - Deals and Alliances Profile

Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365, a potent and selective small molecule inhibitor of CDK7 that is used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors provides gene regulation, new medicines de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch